Total Ankle Replacement
Total Ankle Replacement in the Literature
Hintermann Series H2™ Literature
FOR IMMEDIATE RELEASE:
DT MedTech Announces Successful Total Ankle Revision Procedures Using The New Hintermann Series H2™ Tibial Assembly Component and PE Inlay.
February 14, 2018 (Baltimore, MD) – DT MedTech, LLC (DTM) announced today that their new Hintermann Series H2™ Tibial Assembly component and PE inlay have been successfully implanted by Prof. Beat Hintermann in three patients needing total ankle revision surgery. World-renowned foot and ankle surgeon, Prof. Hintermann, developed the new, versatile, two-component, semi-constrained total ankle replacement prosthesis, Hintermann Series H2™, to be used for primary replacement and revision surgery.*
This most recent revision surgery successfully accommodated the position of the patient's existing anatomy through use of the H2 tibial assembly and PE inlay to convert an unstable, mal-positioned, mobile-bearing tibial component to a semi-constrained prosthesis. According to Prof. Hintermann, the procedure provided stability to the joint with little to no modifications to the existing cuts and anatomy. Postoperatively, patients are able to bear full weigh within the first 24 hours.
Another recent revision procedure resulted in a successful implantation of a functioning H2 ankle to a previously fused ankle due to a mal-alignment from failed arthrodesis surgery. Prof. Hintermann stated, "The new Hintermann Series H2™ is the first customized ankle prosthesis in the marketplace that provides intrinsic stability of the ankle, protecting ligaments and tendons from overload. This reduces pain originating from soft tissue and will provide more stability against translational forces such as walking down the stairs or along uneven ground. Less complications by overloaded periarticular structures, lowers the incidence for future revisions."
DTM's Hintermann Series H2™ sales and distribution in the United States will begin in late March and will be handled directly through its logistics partner, HealthLink Europe International, from its US headquarters in Raleigh, NC, and through specialized and select distributors. Sales and distribution outside of the United States are being handled through HealthLink Europe BV, from its Netherlands location, and other specialized and select distributors.
David Reicher, President and Chief Executive Officer of DTM, stated, "We knew Prof. Hintermann had designed an effective ankle that was versatile and functional when he developed the Hintermann Series H2™ Total Ankle Replacement prosthesis. We are thrilled with the full implantations and revisions we have seen with this exceptional H2 product and are looking forward to its global launch. I believe the Hintermann Series H2™ will be a real game changer within the industry."
For additional DTM information inside the United States, please email info@DTMedTech.com or call Ms. Jeannie Sarda at +1 410-427-0003; outside the United States, please email email@example.com or call +31 73 303 2537.
About DT MedTech, LLC
DT MedTech, LLC is the parent company of DT MedTech International Limited and European Foot Platform, S.A.R.L. DTM and its subsidiary companies maintain offices in Baltimore, Maryland; Dublin, Ireland; Saint-Louis, France; and Liestal, Switzerland. As a member of the Data Trace family of businesses, leaders in scientific and medical publishing, marketing, surgical training, clinical trial management, medical malpractice insurance, and information services for more than 30 years, DTM provides innovative surgical solutions for lower extremity surgeons with state-of-the-art devices such as The Hintermann Series Total Ankle Replacement Systems.
*The Hintermann Series H2™ Total Ankle Replacement (Hintermann Series H2™) system is designed to treat ankle arthritis through replacement of the ankle joint with a prosthesis, thereby reducing pain, restoring alignment, replacing flexion and extension movement in the ankle joint, and allowing for movement at the replaced joint. The Hintermann Series H2™ is indicated as a total ankle replacement in primary or revision surgery of ankle joints damaged by systemic arthritis of the ankle primary arthritis), secondary arthritis. The Hintermann Series H2™ is also indicated for patients with a failed previous ankle surgery and revision surgeries following failed total ankle replacement or non‐union/mal‐union of an ankle arthrodesis, provided sufficient bone stock is present. In the United States, this device is intended for cemented use only.
Press Releases Archive
- 02/07/2018 DT MedTech Announces Successful Implantations of the New Hintermann Series H2™ Total Ankle Replacement Prosthesis.
- 11/08/2017 DT MedTech Announces 510(k) FDA Clearance for Hintermann Series H2™ Total Ankle Replacement System
- 08/15/2016 DT MedTech Secures CE Marking and begins Active Distribution of Hintermann Series H3™ Lower Extremity Medical Devices
- 04/29/2016 DT MedTech Assumes Production and Distribution of Hintermann Series™ Lower Extremity Medical Devices
- 02/29/2016 DT MedTech Acquires Worldwide Ownership of Hintermann Series of Lower Extremity Replacement and Revision Medical Devices
Original Text by Clifford R. Wheeless, III, MD.
Last updated by Data Trace Staff on Friday, July 20, 2018 3:26 pm